Abcam board of directors
|
|
David Cleevely is the Chairman of the Communications Research Network, part of the Cambridge MIT Institute, and the founder and former Chairman of telecoms consultancy Analysys (acquired by Datatec International in 2004). In 1998, he co-founded Abcam with Jonathan Milner (CEO) and Tony Kouzarides. He has been directly involved with 3WayNetworks, Hotxt, Bango, Cambridge Network and Cambridge Wireless. He is also a member of the Ofcom Spectrum Advisory Board, the Expert Panel for the Department of Media, Culture and Sport and the IET Telecoms Sector Panel. Since selling Analysys he has continued to develop his business and academic interests and he currently holds an Industrial Fellowship at the University of Cambridge Computer Laboratory. |
|
|
Jonathan Milner has a degree in Applied Biology from Bath University and a PhD in Molecular Genetics from Leicester University. From 1992 to 1995, he was a research fellow for Pfizer Pharmaceuticals in the laboratory of Professor Tony Rees at the University of Bath, and from 1995 until 1998, he was a research fellow at Cambridge University in the laboratory of Professor Tony Kouzarides, where he studied genes and proteins associated with human cancers. While working at this research he saw the opportunity to market antibodies created by the human genome project over the internet, which was becoming increasingly popular at that time, and in February 1998 he proceeded to found Abcam with David Cleevely and Tony Kouzarides. |
|
|
Jim Warwick has a degree in Computer Science from Cambridge University. From 1986 to 2003 he worked for Analysys Ltd, a Cambridge based telecoms consultancy, heading up their IT, software and web development initiatives. During this period he also held a number of external nonexecutive directorships including Workbench Software Ltd, a start-up with a targeted software package for time recording systems and VBN Ltd, a web-based hosting company specialising in business cluster and innovation network solutions. He joined Abcam in 2001 as Technical Director, initially part time then full time from 2003. He has overseen the expansion of Abcam's bespoke web-based systems. Jim was promoted to Managing Director of Abcam Ltd in June 2004. |
|
|
Jeff Iliffe is a qualified accountant who worked as a corporate financier in life sciences at Panmure Gordon & Co between 1989 and 1996. He then moved into industry, holding a number of financial positions at companies including the environmental consultancy Enviros Group Limited and the biotechnology company Plethora Solutions plc. Prior to joining Abcam as a financial consultant, he was chief financial officer at St Minver Limited, an e-commerce company that operates online gaming networks. |
|
|
Mark Webster joined Abbott Laboratories in 1988 in the UK before moving to Montreal, Canada, and then to Chicago, the USA, where he worked for Abbott's US Pharmaceutical Division as Vice President and General Manager Anti Virals, launching the Kaletra for HIV infection, which became a US$1bn-plus product. He then joined Shire Pharmaceuticals as Head of Global Strategic Marketing and Licensing/Acquisitions. In 2004, he moved to Bayer Healthcare Germany, where he was Senior Vice President, Head of Global Strategic Marketing and Licensing/Acquisitions and a member of Bayer Pharmaceutical's Management Committee. Mark has a degree in Chemistry from Durham University. |
|
|
Tony Kouzarides has a degree in molecular genetics from Leeds University and a Ph.D. in virology from Cambridge University. He was subsequently awarded a research fellowship from Fitzwilliam College, Cambridge. From 1986 to 1989, he spent three years working as a research fellow in the laboratory of Professor Ed Ziff at New York University Medical Centre where he discovered a fundamental principle underlying the association of proteins involved in human cancer. He was awarded a professorship at Cambridge University in 1999 and now oversees a group of scientists studying genes and proteins associated with human cancers. He has played a central role in expanding Abcam's own antibody product range into the Chromatin research area. |
|
|
Peter Keen has over 20 years experience in the financing and management of biotechnology companies. He was Finance Director of Chiroscience Group plc, which he co-founded and whose IPO he led. He then helped establish Merlin Biosciences, where he was UK Managing Director. More recently, he was CFO of Arakis Ltd until its successful trade sale in 2005. He is currently a Non-Executive Director of Ark Therapeutics plc and the Finsbury Emerging Biotechnology Trust plc and acts as an advisor to various other organisations. |
|
|
Tim Dye was until recently the Chief Executive of William Ransom & Son plc, as well as a Director of Noble Troy Ltd. William Ranson is an AIM-quoted business specialising in the manufacture, sales and marketing of natural healthcare products. Through a series of successful acquisitions, he has led the transformation of William Ransom into one of the UK's largest natural healthcare groups. Prior to joining Ransom in 1999, and following an early career as a strategy consultant, he founded and ran businesses in automated meter reading, environmental management and property development. He has a degree in Economics from Cambridge University. |
